Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Modafinil reduces depression's severity when taken with antidepressants

28.11.2013
Researchers believe findings could help the many individuals for whom anti-depressants offer little or no relief

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

The study, a collaboration between the Universities of Cambridge and East London and King's College London, was published online in the Journal of Clinical Psychiatry.

Approximately a third of depressed patients receive little or no benefit from taking antidepressants even when used in combination with psychological counseling. Furthermore, of those who respond to treatment, residual symptoms such as fatigue and trouble sleeping pose risk factors for relapse. The authors of the study believe that these individuals in particular would benefit the most from supplementing their antidepressants with modafinil.

Professor Barbara Sahakian from the University of Cambridge said, "Modafinil has actions on a number of neurotransmitter systems. This may explain why adding it to traditional anti-depressants, such as selective serotonin reuptake inhibitors, has beneficial effects on the symptoms experienced by depressed patients."

"This is good news for individuals struggling to fight depression," said Professor Cynthia Fu from University of East London, who undertook the research whilst at King's College London. "Depression affects all aspects of life, leading to occupational and social disability at varying levels. It is particularly important that people receive effective treatment as the residual symptoms - e.g. fatigue, lack of concentration etc. - can persist and have a negative impact in people's lives."

For the research, the scientists reviewed various studies which had examined the use of modafinil as an add-on treatment for depression. The meta-analysis involved a total of 568 patients with unipolar depression and a total of 342 patients with bipolar depression. The analysis revealed that modafinil improved the severity of depression as well as remission rates. Modafinil also showed beneficial effects on fatigue and sleepiness, with the added benefit of the comparable side effects to placebo.

The research also revealed that the symptomatic benefits of modafinil might also have implications for improving the difficulty of functioning at work sometimes caused by depression. This is significant because depression is a major cause of absenteeism (absence due to sick leave) and presenteeism (present at work but not functioning as before).

Dr Muzaffer Kaser from the University of Cambridge added: "The next step is for longer trials to evaluate potential benefits of supplementing antidepressants with modafinil more comprehensively."

Depression is a major global health problem. According to the World Health Organisation, it is estimated to be the second leading cause of disability worldwide by 2020. Recent studies revealed that depression represents more than a third of global burden of disease attributable to mental health problems*. The annual cost of mood disorders to the UK economy is estimated to be around £16 billion**. Disability caused by depression is mainly due to the negative impact on work and social functioning and its relapsing nature.

For additional information please contact:

Genevieve Maul, Office of Communications, University of Cambridge
Tel: direct, +44 (0) 1223 765542, +44 (0) 1223 332300
Mob: +44 (0) 7774 017464
Email: Genevieve.maul@admin.cam.ac.uk
Notes to editors:

1. The paper 'Modafinil Augmentation Therapy in Unipolar and Bipolar Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials' is published in the November edition of Journal of Clinical Psychiatry.

2. *Whiteford HA. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet doi:10.1016/S0140-6736(13)61611-6

**Fineberg, NA, et al. "The size, burden and cost of disorders of the brain in the UK." Journal of Psychopharmacology 27.9 (2013): 761-770

3. Acknowledgements: Dr Kaser is a PhD student funded by IDB-Cambridge International Scholarship and he receives support from his affiliated institution, Bahcesehir University, Istanbul, Turkey. Dr Costafreda is supported by a National Institute for Health Research Clinical Lecturer post and receives research support funding from South London and Maudsley Biomedical Research Unit in Dementia. Professor Barbara J Sahakian is funded by a grant from the Wellcome Trust and the BCNI is jointly-funded by the Medical Research Council and Wellcome Trust. Professor Cynthia H.Y. Fu is funded by a personal Chair in the School of Psychology, UEL.

3. About King's College London

King's College London is one of the top 20 universities in the world (2013/14 QS World University Rankings) and the fourth oldest in England. It is The Sunday Times 'Best University for Graduate Employment 2012/13'. A research-led university based in the heart of London, King's has more than 25,000 students (of whom more than 10,000 are graduate students) from nearly 140 countries, and more than 6,500 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.

King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £554 million.

King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: http://www.kingshealthpartners.org.

The College is in the midst of a five-year, £500 million fundraising campaign - World questions|King's answers - created to address some of the most pressing challenges facing humanity as quickly as feasible. The campaign's five priority areas are neuroscience and mental health, leadership and society, cancer, global power and children's health. More information about the campaign is available at http://www.kcl.ac.uk/kingsanswers.

4. About the University of East London

The University of East London (UEL) is a global learning community with over 28,000 students from over 120 countries worldwide. Our vision is to achieve national and international recognition as a successful and inclusive university proud of its diversity, committed to new modes of learning which focus on students and enhance their employability, and renowned for our contribution to social, cultural and economic development, especially through our research and scholarship. We have a strong track-record in widening participation and working with industry.

By 2015 UEL aims to be the leading modern university for research in the UK. UEL is an innovative academic community, delivering high-quality research that is impactful, intellectually stimulating, socially relevant and for the public good. UEL is recognised by the academic community throughout the world for our high-quality research, theory and practice, and for our innovation and vitality.

Genevieve Maul | EurekAlert!
Further information:
http://www.cam.ac.uk

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>